Indeed this is good news. Having one stop-codon mutation myself, I have been following several studies with read-through compounds with great interest, like aminoglycoside antibiotics and Ataluren (ptc124).
Unfortunately, although promising in vitro and in animal models, in vivo phase 2 studies have not been successful so far. But I think this is still an approach that could be revolutionar, not least because there many genetic diseases (for instance Duchenne) that could be cured with an effective read-through compound medication.